Please login to the form below

Not currently logged in
Email:
Password:

BMS and AZ gain approval for diabetes drug

The European Commission has granted marketing authorisation for Onglyza throughout the EU

The European Commission has granted marketing authorisation for the diabetes treatment Onglyza (saxagliptin) throughout the European Union(EU).

The once-daily 5 mg oral tablet dose is indicated in adult patients with type 2 diabetes mellitus in combination with other therapies (metformin, sulphonylurea, or thiazolidinedione) subject to certain criteria.

It was developed by Bristol-Myers Squibb(B-MS) and AstraZeneca(AZ) and is the first drug to be launched in Europe as part of the ongoing R&D collaboration between the two companies.

Béatrice Cazala, Bristol-Myers Squibb's president, Europe, and president, global commercialization, said: "The European Commission decision marks an important milestone in the alliance between Bristol-Myers Squibb and AstraZeneca."

Ulf Sather, AstraZeneca's regional vice president for Europe, commented: "Today's announcement is good news for those affected by type 2 diabetes and further demonstrates the commitment of AstraZeneca and Bristol-Myers Squibb to bring much needed options for the treatment of type 2 diabetes."

6th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics